David M. Harlan, MD
Co-Director, Diabetes Center of Excellence,
The William and Doris Krupp Professor of Medicine,
Director, Breakthrough T1D Barbara Dewey Cammett Center of Excellence in New England
Diabetes Care
While chief of the Diabetes Division at UMass Memorial, Dr. Harlan increased volume and significantly improved the level of care in the adult diabetes clinic. He leads by example and strives to improve care delivery systems. Dr. Harlan's patients have benefited from his extensive knowledge of the disease and his ability to listen to each individual and work with them to develop a diabetes management plan. He believes that the person living with diabetes is the most critical member of their care team.
Type 1 Diabetes Research
Over the past 40 years as a physician-scientist, Dr. Harlan has led basic and clinical research exploring the pathophysiology of diabetes. His clinical trials are testing new therapies and investigating human biology related to diabetes and its treatment. His current research is focused on beta cell biology and the anti-beta cell immune response underlying type 1 diabetes.
In the News
JDRF Appoints David Harlan, MD, as Director of their New England Research Collaboration
Dr. Harlan's professional passion became personal with his son's diagnosis of Type 1 diabetes, as mentioned in this Spectrum News coverage of the JDRF (now Breakthrough T1D) appointing him as Director of the regional research collaboration. In this video, he explains how the scientists are executing their plan to cure Type 1 diabetes.
Additional News Coverage
Rachmiel Levine Award | City of Hope Levine-Riggs Diabetes Research Symposium
HLA Class II antigen processing and presentation pathway components demonstrated by transcriptome and protein analyses of beta cells from donors with type 1 diabetes
We resolved a three-decades-long debate by definitively showing that beta cells express these important immune pathway gene products
T1D Pathogenesis: Lessons Learned & Forgotten and Open Questions
This talk highlights progress made in diabetes treatments, comparing old vs. new ideas, and challenges common assumptions & dogmas about Type 1 diabetes